Cargando…
Selective inhibition of cyclooxygenase‐2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood
Enflicoxib is approved for the treatment of pain and inflammation in canine osteoarthritis. The objective of this work was to assess the mechanistic basis of enflicoxib therapy investigating the COX inhibitory activity of enflicoxib (racemate), its enantiomers and its main metabolites using the cani...
Autores principales: | Solà, Josep, Menargues, Àngel, Homedes, Josep, Salichs, Marta, Álvarez, Inés, Romero, Luz, Vela, José Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306928/ https://www.ncbi.nlm.nih.gov/pubmed/35038171 http://dx.doi.org/10.1111/jvp.13042 |
Ejemplares similares
-
Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways
por: Solà, Josep, et al.
Publicado: (2021) -
Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration
por: Homedes, Josep, et al.
Publicado: (2021) -
Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib
por: Salichs, Marta, et al.
Publicado: (2022) -
Evaluation of the Genotoxic Potential of the Selective COX-2
Inhibitor Enflicoxib in a Battery of
in vitro
and
in vivo
Genotoxicity Assays
por: Guzmán, Antonio, et al.
Publicado: (2022) -
Long-term safety evaluation of Daxocox(®) tablets (enflicoxib) in dogs after weekly oral administrations for seven months
por: Homedes, Josep, et al.
Publicado: (2021)